首页> 外文期刊>British Journal of Clinical Pharmacology >Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate.
【24h】

Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate.

机译:口服消旋体后,同时拟合R-和S-布洛芬的血浆浓度。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: To assess the pharmacokinetic equivalence of two different formulations of ibuprofen lysinate with special focus on the expected effects. METHODS: Sixteen healthy volunteers received cross-over ibuprofen lysinate as either one tablet of 400 mg ('test') or two tablets of 200 mg ('reference'). Ibuprofen plasma concentrations were followed up for 10 h. Bioequivalence was assessed by standard noncompartmental methods. Ibuprofen plasma concentrations were fitted with a model that took bioinversion of R- to S-ibuprofen into account. RESULTS: Peak plasma concentrations of R- and S-ibuprofen were 18.1 and 20 microg ml(-1) (test), and 18.2 and 20 microg ml(-1) (reference). Areas under the plasma concentration vs. time curves were 39.7 and 67.5 microg ml(-1) h (test), and 41.1 and 68.2 microg ml(-1) h (reference). Clearance of R-ibuprofen was 5.2 (test) and 5 l h(-1) (reference). A specific plasma concentration was reached with the test formulation about 5 min later than with the reference. Parameters from compartmental modelling were (given for R-and then for S-ibuprofen): body clearance: 4.9 and 4.64 l h(-1), central volume of distribution: 2.8 and 4.1 l, intercompartment clearance: 5.1 and 5.45 l h(-1), peripheral volume of distribution: 4.1 and 5.2 l. The absorption rate constant was 1.52 h(-1), and the test but not the reference formulation had a lag time of 0.1 h. Simulations showed similarity between formulations of the expected effects except for a calculated delay of 6 min with the test formulation. CONCLUSIONS: Ibuprofen formulations were bioequivalent. The pharmacokinetic model may serve as a basis for future pharmacokinetic/pharmacodynamic calculations after administration of racemic ibuprofen.
机译:目的:评估布洛芬赖氨酸盐的两种不同制剂的药代动力学等效性,特别关注预期效果。方法:十六名健康志愿者接受交叉布洛芬赖氨酸盐治疗,一剂400毫克(“测试”)或两片剂200毫克(“参考”)。对布洛芬血浆浓度进行随访10 h。通过标准非房室方法评估生物等效性。布洛芬血浆浓度符合考虑R-转化为S-布洛芬的模型。结果:R-和S-布洛芬的血浆峰值浓度分别为18.1和20微克ml(-1)(测试),18.2和20微克ml(-1)(参考)。血浆浓度与时间的关系曲线下的面积为39.7和67.5 microg ml(-1)h(测试),以及41.1和68.2 microg ml(-1)h(参考)。 R-布洛芬的清除率为5.2(测试)和5 lh(-1)(参考)。测试制剂比参照物晚约5分钟达到特定血浆浓度。隔室建模的参数是(给定R-,然后给S-布洛芬):身体间隙:4.9和4.64 lh(-1),中央分配容积:2.8和4.1 l,室间间隙:5.1和5.45 lh(-1 ),外围分布体积:4.1和5.2 l。吸收速率常数为1.52 h(-1),测试但不是参考配方的滞后时间为0.1 h。模拟显示了预期效果的制剂之间的相似性,所计算的测试制剂延迟为6分钟。结论:布洛芬制剂具有生物等效性。外消旋布洛芬给药后,药代动力学模型可作为未来药代动力学/药效学计算的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号